CANNAINVESTOR Magazine U.S. Publicly Traded May/June 2018 | Page 273

PIONEERING NANO-BIOTECHNOLOGY COMPANY. WITH OVER 20 YEARS RESEARCHING AND DEVELOPING OUR PATENT-PENDING NANOSPHERE DELIVERY SYSTEM™.

PATENTED NANOSPHERE DELIVERY TECHNOLOGY™ INCREASES THE BIOAVAILABILITY AND BIOACTIVITY OF CANNABINOIDS.

NANOSPHERE HEALTH IS THE FIRST AND ONLY COMPANY TO NANO-SIZE AND ENCAPSULATE CANNABINOIDS, DRAMATICALLY CHANGING THE INDUSTRY.

21

Kate S. Wells

CMO

NanoSphere Health Sciences, Inc.

d: 720.528.4437 | c: 303.324.7358

www.nanospherehealth.com

CSE: NSHS

21

PIONEERING NANO-BIOTECHNOLOGY COMPANY. WITH OVER 20 YEARS RESEARCHING AND DEVELOPING OUR PATENT-PENDING NANOSPHERE DELIVERY SYSTEM™.

PATENTED NANOSPHERE DELIVERY TECHNOLOGY™ INCREASES THE BIOAVAILABILITY AND BIOACTIVITY OF CANNABINOIDS.

NANOSPHERE HEALTH IS THE FIRST AND ONLY COMPANY TO NANO-SIZE AND ENCAPSULATE CANNABINOIDS, DRAMATICALLY CHANGING THE INDUSTRY.

273